New asthma drug trial aims to help kids breathe easier
NCT ID NCT05222529
First seen Oct 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study is testing two doses of an inhaled medicine called glycopyrronium in children aged 6 to 12 with moderate to severe asthma. The goal is to see how well it opens up the airways and how safe it is compared to a placebo. The results will help decide the right dose for a future combination asthma treatment. About 42 children will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGRousse, 7002, Bulgaria
-
Novartis Investigative Site
RECRUITINGSevlievo, 5400, Bulgaria
-
Novartis Investigative Site
RECRUITINGSofia, 1510, Bulgaria
-
Novartis Investigative Site
RECRUITINGIbague, Tolima Department, 730006, Colombia
-
Novartis Investigative Site
WITHDRAWNGuatemala City, GTM, 01010, Guatemala
-
Novartis Investigative Site
RECRUITINGGuatemala City, 01015, Guatemala
-
Novartis Investigative Site
RECRUITINGDebrecen, Hajdu Bihar Megye, 4032, Hungary
-
Novartis Investigative Site
RECRUITINGBudapest, 1033, Hungary
-
Novartis Investigative Site
RECRUITINGBudapest, H-1083, Hungary
-
Novartis Investigative Site
RECRUITINGEger, 3300, Hungary
-
Novartis Investigative Site
WITHDRAWNKaposvár, 7400, Hungary
-
Novartis Investigative Site
WITHDRAWNNagykanizsa, 8800, Hungary
-
Novartis Investigative Site
RECRUITINGSzigetvár, 7900, Hungary
-
Novartis Investigative Site
RECRUITINGTarnów, 33-100, Poland
-
Novartis Investigative Site
RECRUITINGLodz, Łódź Voivodeship, 90-329, Poland
-
Novartis Investigative Site
RECRUITINGGeorge, Western Cape, 6529, South Africa
-
Novartis Investigative Site
RECRUITINGCape Town, 7531, South Africa
-
Novartis Investigative Site
RECRUITINGEsplugues, Barcelona, 08950, Spain
-
Novartis Investigative Site
RECRUITINGSabadell, Barcelona, 08208, Spain
-
Novartis Investigative Site
WITHDRAWNMérida, Extremadura, 06800, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGLondon, SE5 9RS, United Kingdom
-
Novartis Investigative Site
RECRUITINGStoke-on-Trent, ST4 6QG, United Kingdom
Conditions
Explore the condition pages connected to this study.